Extended Data Fig. 2: Tc9 cells control the growth of ALV chimeric tumors.
a, Schema of experiments in Fig. 1e. b, Relative Pmel mRNA expression (n = 3 biologically independent samples per group) and gp100 protein level (one of two independent experiments) in WT B16 and B16gp100-kd cells. c, Schema of experiments in Fig. 1f. d, Schema of experiments in Extended Data Fig. 1e. e, Thy1.1+ Pmel-1 Tc1, Tsm, Tcm, or Tc9 cells were transferred into CD45.2+ B6 mice bearing B16 chimeric tumors with the adjuvant treatment, and tumor growth curve were shown (n = 6 mice per group). f, Schema of experiments in Fig. 1g. g, Western blot detection of gp100 protein level in WT B16 and B16gp100-ko cells (one of two independent experiments). h, Schema of experiments in Extended Data Fig. 2i. i, PBS, Thy1.1+ Pmel-1 Tc1 or Tc9 cells were transferred into CD45.2+ B6 mice bearing B16 chimeric (B16 + B16 gp100-ko) tumors with the adjuvant treatment, and tumor growth curve were shown (PBS, n = 3 mice; Tc1, n = 6 mice; Tc9, n = 6 mice). Data are presented as mean ± SEM. Multiple t tests-one per row were used to compare tumor growth in e (day 35), i (day 35); Two-tailed unpaired Student’s t-test was used in b.
